Oppenheimer set a $50.00 price target on The Medicines (NASDAQ:MDCO) in a report published on Monday. The brokerage currently has a buy rating on the stock. Oppenheimer also issued estimates for The Medicines’ Q1 2018 earnings at ($0.64) EPS, Q2 2018 earnings at ($0.63) EPS, Q3 2018 earnings at ($0.44) EPS, Q4 2018 earnings at ($0.45) EPS, FY2018 earnings at ($2.10) EPS, FY2019 earnings at ($2.20) EPS, FY2020 earnings at ($2.48) EPS, FY2021 earnings at ($1.44) EPS and FY2022 earnings at $0.93 EPS.
Several other equities research analysts also recently weighed in on MDCO. Citigroup raised The Medicines from a sell rating to an outperform rating in a research report on Thursday, November 30th. ValuEngine raised The Medicines from a sell rating to a hold rating in a research report on Friday, December 1st. Zacks Investment Research downgraded The Medicines from a hold rating to a sell rating in a research report on Tuesday, December 26th. JPMorgan Chase & Co. reaffirmed an overweight rating and set a $45.00 price target on shares of The Medicines in a research report on Wednesday, January 24th. Finally, Chardan Capital reaffirmed a buy rating and set a $85.00 price target on shares of The Medicines in a research report on Wednesday, January 24th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The Medicines has an average rating of Buy and a consensus price target of $51.00.
Shares of The Medicines (NASDAQ:MDCO) opened at $34.43 on Monday. The firm has a market capitalization of $2,510.00, a PE ratio of -5.18 and a beta of 0.74. The company has a debt-to-equity ratio of 26.06, a quick ratio of 3.18 and a current ratio of 3.21. The Medicines has a 12-month low of $24.45 and a 12-month high of $55.95.
In other news, CEO Clive Meanwell sold 136,250 shares of the firm’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $27.24, for a total transaction of $3,711,450.00. Following the sale, the chief executive officer now directly owns 587,652 shares in the company, valued at approximately $16,007,640.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.22% of the stock is owned by company insiders.
Several large investors have recently bought and sold shares of MDCO. Slate Path Capital LP grew its position in shares of The Medicines by 55.9% during the 4th quarter. Slate Path Capital LP now owns 1,730,000 shares of the company’s stock valued at $47,298,000 after acquiring an additional 620,000 shares during the period. Carillon Tower Advisers Inc. acquired a new stake in The Medicines in the 4th quarter valued at approximately $15,278,000. Westfield Capital Management Co. LP increased its holdings in The Medicines by 21.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,476,778 shares of the company’s stock valued at $91,740,000 after purchasing an additional 445,419 shares during the last quarter. Iridian Asset Management LLC CT increased its holdings in The Medicines by 23.2% in the 4th quarter. Iridian Asset Management LLC CT now owns 2,170,215 shares of the company’s stock valued at $59,334,000 after purchasing an additional 408,177 shares during the last quarter. Finally, Broadfin Capital LLC acquired a new stake in The Medicines in the 4th quarter valued at approximately $10,015,000.
WARNING: This article was first published by BBNS and is the property of of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/15/the-medicines-mdco-given-a-50-00-price-target-by-oppenheimer-analysts-2/2037255.html.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.